Comparison of viraemia and nasal shedding after PRRSV-1 challenge following vaccination with three commercially available PRRS modified live virus vaccines.

Autor: Hancox L; Zoetis UK Ltd, Birchwood Building, Springfield Drive, Leatherhead KT22 7LP, United Kingdom. Electronic address: laura.hancox@zoetis.com., Balasch M; Zoetis Manufacturing and Research Spain S.L., Carretera Camprodon s/n, Finca La Riba, Vall de Bianya, 17813 Girona, Spain., Angulo J; Zoetis Inc., 1040 Swabia Ct, Durham, NC 27703, United States., Scott-Baird E; Drayton Animal Health, Alcester Road, Stratford-upon-Avon, Warwickshire CV37 9RQ, UK., Mah CK; Zoetis Thailand Ltd., 323 United Center Building, 46th Floor, Silom Road, Silom Bangrak, Bangkok 10500, Thailand.
Jazyk: angličtina
Zdroj: Research in veterinary science [Res Vet Sci] 2024 Nov; Vol. 180, pp. 105416. Date of Electronic Publication: 2024 Sep 13.
DOI: 10.1016/j.rvsc.2024.105416
Abstrakt: The effectiveness of three Porcine Reproductive and Respiratory Syndrome (PRRS) Modified Live Virus (MLV) vaccines against PRRSV viraemia and nasal shedding following experimental challenge was compared. The study comprised a negative control (T01), and three treatment groups (T02, T03 and T04) each vaccinated with a single dose of a commercial PRRS MLV vaccine, given in accordance with the vaccine's Summary of Product Characteristics (SPC). Pigs aged 21 days were vaccinated (day 0), challenged intranasally (day 28) with heterologous PRRSV-1-1 strain Olot/91, then monitored for PRRSV viraemia and nasal shedding for 12 days. After challenge, pigs were viraemic on fewer days in group T04 (0.67) than groups T01 (0.91), T02 (0.81) and T03 (0.97) (P < 0.0296). From day 34, inclusive, serum PRRSV titres were lower in group T04 than negative controls (P ≤ 0.0001) and groups T02 and T03 (P ≤ 0.0047); serum PRRSV titre Area Under the Curve (AUC) for group T04 (42.34) was lower than in T01 (65.49), T02 (60.67) and T03 (67.38) (P < 0.0100); pigs exhibited nasal shedding on fewer days in group T04 (0.40) than T01 (0.78), T02 (0.64) and T03 (0.56) (P < 0.0101); and nasal shedding AUC for group T04 (8.52) was lower than in groups T01 (23.59, P < 0.0001) and T02 (19.37, P = 0.0001). The ability of PRRS MLV vaccines to reduce the duration of viraemia and nasal shedding after intranasal challenge with a heterologous PRRSV-1-1 strain differ significantly.
Competing Interests: Declaration of competing interest The authors of this research paper are employees of the sponsoring company, E. Scott-Baird excepted.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: